Fibroblast growth factor 23 and anemia in the chronic renal insufficiency cohort study

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 11, 2017, Pages 1795-1803

  Mehta, Rupal ^a   Cai, Xuan ^a   Hodakowski, Alexander ^a   Lee, Jungwha ^a   Leonard, Mary ^b   Ricardo, Ana ^c   Chen, Jing ^d   Hamm, Lee ^d   Sondheimer, James ^e   Dobre, Mirela ^f   David, Valentin ^a   Yang, Wei ^g   Go, Alan ^h   Kusek, John W ⁱ   Feldman, Harold ^g   Wolf, Myles ^j   Isakova, Tamara ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Anemia; Cardiovascular diseases; Chronic; Confidence intervals; Demography; Erythropoiesis; Erythropoietin; Female; Fibroblast growth factors; Glomerular filtration rate; Hemoglobins; Humans; Male; Mineral metabolism; Minerals; Odds ratio; Prospective studies; Renal insufficiency; Risk factors

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DEMOGRAPHY; DISEASE ASSOCIATION; ERYTHROPOIESIS; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MINERAL METABOLISM; MORBIDITY; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PROSPECTIVE STUDY; SMOKING; SYSTOLIC BLOOD PRESSURE; BLOOD; COMPLICATION; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; ANEMIA; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 85033395412     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03950417     Document Type: Article

References (44)

1. Babitt JL, Lin HY: Mechanisms of anemia in CKD. J AmSoc Nephrol 23: 1631–1634, 2012
2. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38: 955–962, 2001
3. Xu D, Murakoshi N, Sairenchi T, Irie F, Igarashi M, Nogami A, Tomizawa T, Yamaguchi I, Yamagishi K, Iso H, Ota H, Aonuma K: Anemia and reduced kidney function as risk factors for new onset of atrial fibrillation (from the Ibaraki prefectural health study). AmJ Cardiol 115: 328–333, 2015
4. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34: 125–134, 1999
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53–61, 1996
6. Eriksson D, Goldsmith D, Teitsson S, Jackson J, van Nooten F: Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol 17: 97, 2016
7. Alexander M, Kewalramani R, Agodoa I, Globe D: Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin 23: 2997–3008, 2007
8. van Breda F, Emans ME, van der Putten K, Braam B, van Ittersum FJ, Kraaijenhagen RJ, de Borst MH, Vervloet M, Gaillard CA: Relation between red cell distribution width and fibroblast growth factor 23 cleaving in patients with chronic kidney disease and heart failure. PLoS One 10: e0128994, 2015
9. Tsai MH, Leu JG, Fang YW, Liou HH: High fibroblast growth factor 23 levels associated with low hemoglobin levels in patients with chronic kidney sisease stages 3 and 4. Medicine (Baltimore) 95: e3049, 2016
10. Patel NM, Gutiérrez OM, Andress DL, Coyne DW, Levin A, Wolf M: Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 77: 715–720, 2010
11. Cain CJ, Rueda R, McLelland B, Collette NM, Loots GG, Manilay JO: Absence of sclerostin adversely affects B-cell survival. J Bone Miner Res 27: 1451–1461, 2012
12. Horowitz MC, Fretz JA: Sclerostin: A new mediator of crosstalk between the skeletal and immune systems. J Bone Miner Res 27: 1448–1450, 2012
13. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370–1378, 2011
14. Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D: FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem 289: 9795–9810, 2014
15. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: The Chronic Renal Insufficiency Cohort (CRIC) study: Design and methods. J Am Soc Nephrol 14[Suppl 2]: S148–S153, 2003
16. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393–4408, 2011
17. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P; MMKD Study Group: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 18: 2600–2608, 2007
18. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25: 349–360, 2014
19. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Chronic Renal Insufficiency Cohort (CRIC) study: Baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 4: 1302–1311, 2009
20. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009
21. Chen TK, Estrella MM, Astor BC, Greene T, Wang X, Grams ME, Appel LJ: Longitudinal changes in hematocrit in hypertensive chronic kidney disease: Results from the African-American Study of Kidney Disease and Hypertension (AASK). Nephrol Dial Transplant 30: 1329–1335, 2015
22. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M: Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol 24: 125–135, 2013
23. Camaschella C: Iron-deficiency anemia. NEngl J Med372: 1832– 1843, 2015
24. Wolf M, White KE: Coupling fibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23: 411–419, 2014
25. Leshem-Rubinow E, Steinvil A, Zeltser D, Berliner S, Rogowski O, Raz R, Chodick G, Shalev V: Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure. Mayo Clin Proc 87: 1189– 1195, 2012
26. Inoue A, Babazono T, Iwamoto Y: Effects of the renin-angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease. Am J Hypertens 21: 317–322, 2008
27. Gossmann J, Thürmann P, Bachmann T, Weller S, Kachel HG, Schoeppe W, Scheuermann EH: Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 50: 973–978, 1996
28. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C: Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22: 1020–1032, 2015
29. Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenstädt HJ, Meersch M, Unruh M, Zarbock A: FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 126: 962–974, 2016
30. David V, Francis C, Babitt JL: Ironing out the cross talk between FGF23 and inflammation. Am J Physiol Renal Physiol 312: F1–F8, 2017
31. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 352: 1011–1023, 2005
32. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205–2215, 2005
33. Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M: Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol 25: 564–572, 2014
34. Alon DB, Chaimovitz C, Dvilansky A, Lugassy G, Douvdevani A, Shany S, Nathan I: Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp Hematol 30: 403– 409, 2002
35. Zucker S, Friedman S, Lysik RM: Bone marrow erythropoiesis in the anemia of infection, inflammation, and malignancy. J Clin Invest 53: 1132–1138, 1974
36. Iguchi A, Kazama JJ, Yamamoto S, Yoshita K, Watanabe Y, Iino N, Narita I: Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency. Nephron 131: 161–166, 2015
37. Braithwaite V, Prentice AM, Doherty C, Prentice A: FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: A supplementation study. Int J Pediatr Endocrinol 2012: 27, 2012
38. Yamashita K, Mizuiri S, Nishizawa Y, Kenichiro S, Doi S, Masaki T: Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal FGF23 levels of maintenance hemodialysis patients [published online ahead of print August 25, 2016]. Nephrology (Carlton) doi 10.1111/nep.12909
39. David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M: Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89: 135–146, 2016
40. Wolf M, Koch TA, Bregman DB: Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28: 1793–1803, 2013
41. Wolf M: Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 82: 737–747, 2012
42. Smith ER, Cai MM, McMahon LP, Holt SG: Biological variabilityof plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97: 3357–3365, 2012
43. Fellner SK, Lang RM, Neumann A, Korcarz C, Borow KM: Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 44: 1309–1315, 1993
44. Hörl WH: Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 9: 291–301, 2013